InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading national provider of
infusion pumps and related services for the U.S. healthcare industry, today
announced that Institutional Shareholder Services (ISS), a leading independent
proxy advisory service, has recommended a "FOR" vote on all proposals appearing
in the Company's Proxy Statement for the 2014 Annual Meeting of Stockholders to
be held on May 8, 2014.  


Stockholders who have questions in connection with these proposals, or who need
assistance in voting their shares, are asked to call the Company's Proxy
Solicitation firm:


Georgeson Inc.
866-482-4931 

About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related
services to hospitals, oncology practices and other alternate site healthcare
providers. Headquartered in Madison Heights, Michigan, the Company delivers
local, field-based customer support and also operates Centers of Excellence in
Michigan, Kansas, California, Texas and Ontario, Canada. The Company's stock is
traded on the NYSE MKT under the symbol INFU.


Forward-Looking Statements
Certain statements contained in this release are forward-looking statements and
are based on future expectations, plans and prospects for InfuSystem Holdings,
Inc.'s ("InfuSystem," "INFU," "the Company," "We") business and operations that
involve a number of risks and uncertainties. The Company's outlook for 2014 and
other forward-looking statements in this release are made as of April 23, 2014,
and the Company disclaims any duty to supplement, update or revise such
statements on a going-forward basis, whether as a result of subsequent
developments, changed expectations or otherwise. In connection with the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995, the
Company is identifying certain factors that could cause actual results to
differ, perhaps materially, from those indicated by these forward-looking
statements. Those factors, risks and uncertainties include, but are not limited
to, potential changes in overall healthcare reimbursement -- including CMS
competitive bidding, sequestration, concentration of customers, increased focus
on early detection of cancer, competitive treatments, dependency on Medicare
Supplier Number, availability of chemotherapy drugs, global financial
conditions, changes and enforcement of state and federal laws, natural forces,
competition, dependency on suppliers, risks in acquisitions & joint ventures, US
Healthcare Reform, relationships with healthcare professionals and
organizations, technological changes related to infusion therapy, dependency on
websites and intellectual property, the ability of the Company to successfully
integrate acquired businesses, dependency on key personnel, dependency on
banking relations and covenants, and other risks associated with our common
stock, as well as any other litigation to which the Company may be subject from
time to time; and other risk factors as discussed in the Company's annual report
on Form 10-K for the year ended December 31, 2013 and in other filings made by
the Company from time to time with the Securities and Exchange Commission. 


Additional information about InfuSystem Holdings, Inc., including materials
relating to its 2014 Annual Meeting of Stockholders, is available at
www.infusystem.com.



FOR FURTHER INFORMATION PLEASE CONTACT: 

CONTACT: 

Rob Swadosh
The Dilenschneider Group
212-922-0900